AstraZeneca’s Baxfendy Approval Isn’t a Hypertension Win — It’s a $40 Billion Market Wedge
FDA approved AstraZeneca's baxdrostat (Baxfendy) on May 18, 2026 — the first aldosterone synthase inhibitor for hypertension. Here's what...
baxdrostat
FDA approved AstraZeneca's baxdrostat (Baxfendy) on May 18, 2026 — the first aldosterone synthase inhibitor for hypertension. Here's what...